Welcome to our dedicated page for Medicale SEC filings (Ticker: MCLE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medicale's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medicale's regulatory disclosures and financial reporting.
Medicale Corp. reported another small quarterly loss and remains a development-stage company with no revenue and significant financial strain.
For the three months ended December 31, 2025, the company posted a net loss of $5,290, a sharp improvement from a $16,680 loss a year earlier, mainly because operating expenses dropped to $3,144 from $14,995. Interest expense from debt rose modestly to $2,146.
Despite the smaller loss, the balance sheet is very weak. Medicale had cash of $0, current liabilities of $32,202, and a working capital deficit of $32,202 as of December 31, 2025. Total liabilities were $145,376, including $113,174 of convertible notes, while stockholders’ deficit was also $145,376. The accumulated deficit reached $222,288 with 5,920,000 common shares outstanding.
Management states there is substantial doubt about the company’s ability to continue as a going concern and expects to rely on additional investment capital and further convertible note financing to fund basic operating costs while it attempts to launch its dietary supplements consulting and distribution business.
Medicale Corp$41,153, improved from a $58,213 loss in 2024 as operating expenses fell to $33,493, mainly from lower consulting fees.
The balance sheet at September 30, 2025 shows no assets, total liabilities of $140,086, and an accumulated deficit of $216,998, resulting in a stockholders’ deficit of $140,086. Current liabilities rose to $33,652 and are funded largely by $106,434 of non‑current convertible notes from third parties, used to pay operating costs.
The company had $0 cash at year end, a working capital deficit of $33,652, and continues to rely entirely on external financing, primarily convertible notes, after generating no revenue since inception. There were 5,920,000 common shares outstanding and 11 shareholders of record as of January 9, 2026. Management and the auditor both state that recurring losses, negative working capital and lack of revenues create substantial doubt about Medicale’s ability to continue as a going concern.
Medicale Corp. submitted a Form 12b-25 to notify regulators that it will not file its report for the period ended September 30, 2025 on time. The company explains that it could not complete its financial statements without unreasonable effort or expense because of a recent change in auditor. This filing is a standard mechanism that gives the company a short extension to complete and submit the delayed report.